Neuron-specific enolase evaluation in patients with neuroblastoma

Simonetta Massaron, Ettore Seregni, Roberto Luksch, Michela Casanova, Carlo Botti, Leonardo Ferrari, Martinetti Antonio, Silvia Nerini Molteni, Franca Fossati Bellani, Emilio Bombardieri

Research output: Contribution to journalArticlepeer-review


Neuron-specific enolase (NSE) may be of interest for the prognostic evaluation and follow-up surveillance in patients with neuroblastoma. We evaluated NSE levels in 80 patients with neuroblastoma. The marker correlated with stage (in stage 1 patients, the median NSE level was 9.9 ng/ml, in stage 2, 45.1 ng/ml, in stage 3, 49 ng/ml, in stage 4, 93.9 ng/ml, in stage 4S, 53.4 ng/ml) and with survival. In patients with a favorable or a poor outcome, the difference in basal NSE serum levels was statistically significant (p = 0.0001). Serial measurements revealed that there was a good correlation between NSE levels and disease course. We concluded that NSE is a good marker for neuroblastoma and its quantitative determination in serum is valuable in the management of these patients to confirm the diagnosis, monitor the effect of treatment and detect recurrent disease.

Original languageEnglish
Pages (from-to)261-268
Number of pages8
JournalTumor Biology
Issue number4
Publication statusPublished - 1998


  • Enolases
  • Neuroblastoma
  • Neuron-specific enolase
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Neuron-specific enolase evaluation in patients with neuroblastoma'. Together they form a unique fingerprint.

Cite this